# Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tocilizumab-inhibits-structural-joint-damage-in-rheumatoid-arthritis-patients/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Joel M. Kremer,Ricardo Blanco,Marek Brzosko,Rubén Burgos‐Vargas,Anne-Marie Halland,Emma Vernon,Petra Ambs,Roy Fleischmann |
| Citations | 414 |
| DOI | 10.1002/art.30158 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2054059257 |
| PMID | 21360490 |
| Type | article |
| Year | 2010 |

## Paper authors

- [Ricardo Blanco](https://scholariq.org/researchers/ricardo-blanco/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.